Literature DB >> 19738484

Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era.

Leslie Cockerham1, Rebecca Scherzer, Andrew Zolopa, David Rimland, Cora E Lewis, Peter Bacchetti, Carl Grunfeld, Michael Shlipak, Phyllis C Tien.   

Abstract

OBJECTIVE: To determine the relationship of HIV infection, demographic, and cardiovascular disease (CVD) risk factors with mortality in the recent highly active antiretroviral therapy era.
METHODS: Vital status was ascertained from 2004 to 2007 in 922 HIV infected and 280 controls in the Study of Fat Redistribution and Metabolic Change in HIV infection; 469 HIV infected were included in analysis comparing HIV with similar age controls. Multivariable exponential survival regression (adjusting for demographic and CVD factors) estimated hazard ratios (HRs) for death.
RESULTS: After 5 years of follow-up, the overall adjusted mortality HR was 3.4 [95% confidence interval (CI): 1.35-8.5]; HR was 6.3 among HIV infected with CD4 < 200 (95% CI: 2.2-18.2), 4.3 with CD4 200-350 (95% CI: 1.14-16.0), and 2.3 with CD4 > 350 (95% CI: 0.78-6.9). Among HIV infected, current smoking (HR = 2.73 vs. never smokers, 95% CI: 1.64-4.5) and older age (HR = 1.61 per decade, 95% CI: 1.27-2.1) were independent risk factors for death; higher baseline CD4 count was associated with lower risk (HR = 0.65 per CD4 doubling, 95% CI: 0.58-0.73).
CONCLUSIONS: HIV infection was associated with a 3-fold mortality risk compared with controls after adjustment for demographic and CVD risk factors. In addition to low baseline CD4 count, older age and current smoking were strong and independent predictors of mortality in a US cohort of HIV-infected participants in clinical care.

Entities:  

Mesh:

Year:  2010        PMID: 19738484      PMCID: PMC2799541          DOI: 10.1097/QAI.0b013e3181b79d22

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  18 in total

1.  Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

Authors:  M A Hernán; B Brumback; J M Robins
Journal:  Epidemiology       Date:  2000-09       Impact factor: 4.822

Review 2.  Multiple imputation: a primer.

Authors:  J L Schafer
Journal:  Stat Methods Med Res       Date:  1999-03       Impact factor: 3.021

3.  Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras.

Authors:  Nancy F Crum; Robert H Riffenburgh; Scott Wegner; Brian K Agan; Sybil A Tasker; Katherine M Spooner; Adam W Armstrong; Susan Fraser; Mark R Wallace
Journal:  J Acquir Immune Defic Syndr       Date:  2006-02-01       Impact factor: 3.731

4.  Recruitment in the Coronary Artery Disease Risk Development in Young Adults (Cardia) Study.

Authors:  G H Hughes; G Cutter; R Donahue; G D Friedman; S Hulley; E Hunkeler; D R Jacobs; K Liu; S Orden; P Pirie
Journal:  Control Clin Trials       Date:  1987-12

5.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

6.  Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study.

Authors:  A Mocroft; R Brettle; O Kirk; A Blaxhult; J M Parkin; F Antunes; P Francioli; A D'Arminio Monforte; Z Fox; J D Lundgren
Journal:  AIDS       Date:  2002-08-16       Impact factor: 4.177

7.  Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population.

Authors:  Christian Jaggy; Jan von Overbeck; Bruno Ledergerber; Claude Schwarz; Matthias Egger; Martin Rickenbach; Hans-Jakob Furrer; Amalio Telenti; Manuel Battegay; Markus Flepp; Pietro Vernazza; Enos Bernasconi; Bernard Hirschel
Journal:  Lancet       Date:  2003-09-13       Impact factor: 79.321

8.  The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics.

Authors:  Phyllis C Tien; Constance Benson; Andrew R Zolopa; Stephen Sidney; Dennis Osmond; Carl Grunfeld
Journal:  Am J Epidemiol       Date:  2006-03-08       Impact factor: 4.897

9.  CARDIA: study design, recruitment, and some characteristics of the examined subjects.

Authors:  G D Friedman; G R Cutter; R P Donahue; G H Hughes; S B Hulley; D R Jacobs; K Liu; P J Savage
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

10.  HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.

Authors:  Antonella d'Arminio Monforte; Donald Abrams; Christian Pradier; Rainer Weber; Peter Reiss; Fabrice Bonnet; Ole Kirk; Matthew Law; Stephane De Wit; Nina Friis-Møller; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.632

View more
  46 in total

1.  Intermuscular adipose tissue and metabolic associations in HIV infection.

Authors:  Rebecca Scherzer; Wei Shen; Steven B Heymsfield; Cora E Lewis; Donald P Kotler; Mark Punyanitya; Peter Bacchetti; Michael G Shlipak; Carl Grunfeld
Journal:  Obesity (Silver Spring)       Date:  2010-06-10       Impact factor: 5.002

Review 2.  Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010.

Authors:  James D Neaton; Jacqueline Neuhaus; Sean Emery
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

3.  Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosenescence.

Authors:  Jeffrey N Dock; Rita B Effros
Journal:  Aging Dis       Date:  2011-10       Impact factor: 6.745

4.  Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy.

Authors:  Carl Grunfeld; Michael Saag; Joseph Cofrancesco; Cora Elizabeth Lewis; Richard Kronmal; Steven Heymsfield; Phyllis C Tien; Peter Bacchetti; Michael Shlipak; Rebecca Scherzer
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

5.  Risk stratification and prognosis of human immunodeficiency virus-infected patients with known or suspected coronary artery disease referred for stress echocardiography.

Authors:  Omar Wever Pinzon; Jorge Silva Enciso; Jorge Romero; Harikrishna Makani; Jose Fefer; Vani Gandhi; Sripal Bangalore; Farooq A Chaudhry
Journal:  Circ Cardiovasc Imaging       Date:  2011-07-12       Impact factor: 7.792

6.  Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype.

Authors:  Meagan O'Brien; Olivier Manches; Rachel Lubong Sabado; Sonia Jimenez Baranda; Yaming Wang; Isabelle Marie; Linda Rolnitzky; Martin Markowitz; David M Margolis; David Levy; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

7.  The unique challenges facing HIV-positive patients who smoke cigarettes: HIV viremia, ART adherence, engagement in HIV care, and concurrent substance use.

Authors:  Conall O'Cleirigh; Sarah E Valentine; Megan Pinkston; Debra Herman; C Andres Bedoya; Janna R Gordon; Steven A Safren
Journal:  AIDS Behav       Date:  2015-01

8.  A qualitative study of the feasibility and acceptability of a smoking cessation program for people living with HIV and emotional dysregulation.

Authors:  A K Labbe; J G Wilner; J N Coleman; S M Marquez; J D Kosiba; M J Zvolensky; J A J Smits; P J Norton; D Rosenfield; C O'Cleirigh
Journal:  AIDS Care       Date:  2018-10-23

Review 9.  When to start antiretroviral therapy.

Authors:  Vivek Jain; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2010-05       Impact factor: 5.071

10.  Colorectal cancer screening in human immunodeficiency virus population: Are they at average risk?

Authors:  Suresh Kumar Nayudu; Bhavna Balar
Journal:  World J Gastrointest Oncol       Date:  2012-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.